OXFORD BIODYNAMICS PLC

Their core work

Oxford Biodynamics is a UK-based biotechnology SME specialising in epigenetic approaches to disease prediction and patient stratification. Their work centres on applying quantitative modelling to epigenetic data — particularly how gene regulation patterns can predict which patients will respond to specific treatments before those treatments are tried. In H2020, they contributed this predictive biomarker expertise to both a foundational epigenetics training network (PEP-NET) and a large multi-country clinical consortium focused on psoriasis and psoriatic arthritis (HIPPOCRATES). Their practical value lies in translating complex epigenetic signals into clinically actionable decision tools for inflammatory disease management.

What they specialise in

How they've shifted over time

Oxford Biodynamics entered H2020 through PEP-NET (2018), an MSCA training network where their contribution was squarely methodological — quantitative modelling as the bridge between epigenetic theory and experimental data. By 2021, with HIPPOCRATES, the focus shifted decisively toward clinical application: the project's keywords are almost entirely disease-specific and patient-facing, covering treatment response, early diagnosis, and long-term impact in psoriasis and psoriatic arthritis. This arc — from computational methodology to disease-specific clinical tools — suggests a company moving its epigenetic technology closer to healthcare decision-making and away from pure research.

Oxford Biodynamics is on a clear trajectory from foundational epigenetics methods toward clinical application in immune-mediated inflammatory diseases, making them an increasingly relevant partner for precision medicine consortia targeting autoimmune conditions.

How they like to work

Oxford Biodynamics has participated exclusively as a partner or participant — never as a project coordinator — across both H2020 projects. With 42 unique consortium partners across 13 countries, they are embedded in large, multi-partner consortia rather than small focused collaborations. This profile suggests they operate as a specialist technology contributor: they bring a specific capability (epigenetic biomarker analysis) that complements the clinical, academic, and patient-advocacy partners around them, rather than leading the coordination effort.

Oxford Biodynamics has built connections with 42 distinct consortium partners across 13 countries through just two projects, indicating participation in large, geographically diverse consortia. Their network spans both research excellence (MSCA) and health pillar (RIA) projects, suggesting exposure to both academic and clinical partner environments.

What sets them apart

As a private SME — rather than a university or hospital — Oxford Biodynamics brings proprietary epigenetic technology into academic and clinical consortia, offering something most academic partners cannot: a commercial-grade biomarker platform with an eye toward real-world deployment. Their specific combination of computational epigenetics and inflammatory disease focus is narrow enough to be a genuine differentiator in precision medicine projects targeting autoimmune conditions. For consortium builders, they represent a technology transfer bridge between epigenomics research and clinical diagnostics markets.

Highlights from their portfolio

• HIPPOCRATES
  The largest and most clinically focused of their projects, with EUR 249,375 in EC funding, covering five years (2021–2026) across a pan-European consortium targeting psoriasis and psoriatic arthritis — a high-prevalence inflammatory disease pair with significant unmet diagnostic need.
• PEP-NET
  An MSCA Innovative Training Network (2018–2023) that positioned Oxford Biodynamics at the intersection of epigenetics theory and experiment, establishing their credentials as a methodological contributor before their clinical disease focus crystallised.